Human Genome Epidemiology Literature Finder
Records 1 - 19 (of 19 Records) |
Query Trace: Neutropenia and DPYD[original query] |
---|
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. International journal of cancer. Journal international du cancer 2002 Sep 101 (3): 253-8. Van Kuilenburg André B P, Meinsma Rutger, Zoetekouw Lida, Van Gennip Albert |
Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Annals of clinical biochemistry 2003 1 40 (Pt 1): 41-5. van Kuilenburg André B P, De Abreu Ronney A, van Gennip Albert |
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 2009 56 (4): 303-16. Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, Sevcik J, Novotny |
Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. Therapeutic drug monitoring 2013 Oct 35 (5): 624-30. Teh Lay Kek, Hamzah Sharina, Hashim Hazwanie, Bannur Zakaria, Zakaria Zainul Amiruddin, Hasbullani Zakaria, Shia John Kwong Siew, Fijeraid Henry, Md Nor Azmid, Zailani Mohd, Ramasamy Prabu, Ngow Harris, Sood Suneet, Salleh Mohd Za |
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L |
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. Pharmacogenomics 2016 Jun . Cortejoso Lucía, García-González Xandra, García María I, García-Alfonso Pilar, Sanjurjo María, López-Fernández Luis |
Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clinical biochemistry 2016 Jul . Galarza Andrés Fernando Andrade, Linden Rafael, Antunes Marina Venzon, Hahn Roberta Zilles, Raymundo Suziane, da Silva Anne Caroline Cezimbra, Staggemeier Rodrigo, Spilki Fernando Rosado, Schwartsmann Gilber |
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. JAMA oncology 2016 Jan . Boige Valérie, Vincent Marc, Alexandre Philippe, Tejpar Sabine, Landolfi Stefania, Le Malicot Karine, Greil Richard, Cuyle Pieter Jan, Yilmaz Mette, Faroux Roger, Matzdorff Axel, Salazar Ramon, Lepage Côme, Taieb Julien, Laurent-Puig Pier |
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L |
DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer chemotherapy and pharmacology 2017 Nov . Nahid Noor Ahmed, Apu Mohd Nazmul Hasan, Islam Md Reazul, Shabnaz Samia, Chowdhury Surid Mohammad, Ahmed Maizbha Uddin, Nahar Zabun, Islam Md Siddiqul, Islam Mohammad Safiqul, Hasnat Ab |
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. British journal of cancer 2017 Oct 117 (9): 1269-1277. Ruzzo A, Graziano F, Galli Fabio, Galli Francesca, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta M T, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani |
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. European journal of cancer (Oxford, England : 1990) 2018 8 102 31-39. Madi Ayman, Fisher David, Maughan Timothy S, Colley James P, Meade Angela M, Maynard Julie, Humphreys Vikki, Wasan Harpreet, Adams Richard A, Idziaszczyk Shelley, Harris Rebecca, Kaplan Richard S, Cheadle Jeremy |
The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study. British journal of cancer 2019 Mar . Iachetta Francesco, Bonelli Candida, Romagnani Alessandra, Zamponi Raffaella, Tofani Lorenzo, Farnetti Enrico, Nicoli Davide, Damato Angela, Banzi Maria, Casali Bruno, Pinto Carmi |
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. The pharmacogenomics journal 2019 Feb . Del Re Marzia, Cinieri Saverio, Michelucci Angela, Salvadori Stefano, Loupakis Fotios, Schirripa Marta, Cremolini Chiara, Crucitta Stefania, Barbara Cecilia, Di Leo Angelo, Latiano Tiziana Pia, Pietrantonio Filippo, Di Donato Samantha, Simi Paolo, Passardi Alessandro, De Braud Filippo, Altavilla Giuseppe, Zamagni Claudio, Bordonaro Roberto, Butera Alfredo, Maiello Evaristo, Pinto Carmine, Falcone Alfredo, Mazzotti Valentina, Morganti Riccardo, Danesi Roma |
Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population. Avicenna journal of medical biotechnology 0 12 (3): 157-164. Abbasian Mohammad Hadi, Ansarinejad Nafiseh, Abbasi Bahareh, Iravani Masoud, Ramim Tayeb, Hamedi Fahime, Ardekani Ali |
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. British journal of clinical pharmacology 2021 Nov . Božina Nada, Bili? Ivan, Ganoci Lana, Šimi?evi? Livija, Pleština Stjepko, Lešnjakovi? Lucija, Trkulja Vladim |
Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis. Journal of personalized medicine 2022 2 12 (2): . Kim Woorim, Cho Young-Ah, Kim Dong-Chul, Lee Kyung-E |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: